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Abstract
OBJECTIVE—To summarize the approaches used to manage exposure of patients to 
inadequately sterilized neurosurgical instruments contaminated as a result of Creutzfeldt-Jakob 
disease (CJD).
METHODS—Information on past CJD exposure incidents reported to the Centers for Disease 
Control and Prevention (CDC) was aggregated and summarized. In addition, inactivation studies 
were reviewed, and data from selected publications were provided for reference.
RESULTS—Nineteen incidents of patient exposure to potentially CJD-contaminated instruments 
were reported to the CDC, including 17 that involved intracranial procedures and 2 that involved 
ophthalmologic procedures. In more than 50% of incidents, the neurosurgical procedures were 
performed for diagnostic work up of the index patients. At least 12 of the hospitals had multiple 
neurosurgical sets, and the CJD-contaminated instruments could not be identified in 11 of 19 
hospitals. In 12 of 15 hospitals with neurosurgical incidents, a decision was made to notify 
patients of their potential exposure.
CONCLUSIONS—Neurosurgical instruments used for treatment of patients with suspected or 
diagnosed CJD or patients whose diagnosis is unclear should be promptiy identified and sterilized 
using recommended CJD decontamination protocols. Inability to trace instruments complicates 
appropriate management of exposure incidents. The feasibility of instituting instrument tracking 
procedures should be considered.
Creutzfeldt-Jakob disease (CJD) is a rapidly progressive, invariably fatal, neurodegenerative 
disease. It is characterized by accumulation in the brain of abnormal conformers of a host-
encoded protein known as the prion protein.1 These abnormal proteins are believed to 
constitute the key component of “prions,” the proteinaceous infectious agents responsible 
for CJD and other prion diseases.2 In addition to CJD, human prion diseases include variant 
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CJD, kuru, Gerstmann-Straussler-Scheinker syndrome, and sporadic and familial fatal 
insomnia.
CJD usually affects older adults between the ages of 55 and 75 years.3 In approximately 
85% of patients, the disease occurs sporadically without any known external source of 
infection. In 10%–15% of patients, CJD occurs as a familial cluster associated with inherited 
mutations of the prion protein gene. Iatrogenic transmission of CJD has been reported in less 
than 1% of patients, with exposure linked to the use of contaminated cadaveric pituitary 
hormones, dura mater and corneal grafts, and neurosurgical instruments.4 Incubation periods 
typically range from years to decades.
The unusual resistance of prions to inactivation by standard chemical and physical 
decontamination methods led to recommendations for stringent reprocessing measures for 
surgical devices used to treat patients with suspected CJD.5-7 Instrument reprocessing 
should be planned well in advance of patients with known or suspected CJD undergoing a 
surgical procedure. However, some patients may undergo a neurosurgical procedure before 
their CJD diagnosis is suspected or is known to the operating room staff. The CJD-
contaminated instruments may then be reused to treat other patients after reprocessing with 
standard hospital sterilization procedures, potentially exposing patients to inadequately 
sterilized instruments. Such incidents have been reported to the Centers for Disease Control 
and Prevention (CDC). These incidents posed unique challenges to infection prevention 
professionals and hospital management staff, including difficulties in tracing instruments 
used weeks to months earlier on the index patient and in determining the most appropriate 
way to address the issue of patient exposure. Neurosurgical and selected ophthalmologic 
incidents reported to the CDC are summarized in this article, including an outline of 
approaches that can be used to manage similar incidents in other healthcare institutions.
METHODS
The CDC was contacted by US hospitals and state and local health departments when 
patient exposure to inadequately sterilized prion-contaminated surgical instruments was 
identified. Typically, instrument contamination occurred during a neurosurgical procedure 
involving a patient whose CJD diagnosis was confirmed after the procedure. The CDC 
consultation involved assessment of instrument contamination risk and potential CJD 
transmission to other patients who underwent operations soon after the index patient's 
procedure. As part of the consultation, information about the CJD exposure incidents was 
collected, including details about the index patient, surgical and diagnostic procedures, 
surgical equipment circulation, decontamination procedures, and patient exposure and 
notification. This information is aggregated and summarized to facilitate proper handling of 
similar incidents that may occur in other institutions. Examination of the various incidents 
allowed identification of issues pertinent to risk assessment, patient notification, and future 
prevention strategies. These issues and approaches in addressing them are summarized in 
this article.
The core infection control issue in prion diseases is resistance of prions to inactivation by 
conventional chemical and heat sterilization methods.8 Many studies have been done to 
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evaluate prion resistance to various inactivation methods. These inactivation studies were 
reviewed, and data from selected publications were summarized for reference.
RESULTS
CJD Exposure Incidents
From January 1998 to December 2012, 19 incidents of suspected iatrogenic exposure to 
CJD-contaminated instruments were reported to the CDC (Table 1). All of the CJD index 
patients reported as part of these incidents died during this time period. The patient ages 
ranged from 43 to 80 years (mean age, 62 years), and 10 (56%) of the 18 patients with 
available information were female.
Two exposure incidents involved ophthalmologic procedures for cataract removal, whereas 
the remaining 17 incidents involved intracranial procedures for indications listed in Table 1. 
In over half of the patients, the intracranial procedures were probably performed as part of 
the patients’ diagnostic evaluation. At the time of the procedures, operating room personnel 
were unaware of the possible CJD diagnosis in nearly all of the incidents. Hence, 
instruments were reprocessed using conventional methods, and recommended CJD 
decontamination protocols were not followed. For 18 incidents with available information, 
the median elapsed time from the date of the index surgical procedure to CJD suspicion or 
diagnosis was approximately 10 weeks (range, 1 day to 1 year).
At least 12 hospitals had multiple neurosurgical sets, making identification of contaminated 
instruments nearly impossible in some hospitals by the time of CJD diagnosis. For hospitals 
with available information, the number of neuro-surgical sets per hospital ranged from 1 to 
12. Overall, the CJD-contaminated sets could not be identified in 11 (58%) of the 19 
hospitals. In these 11 hospitals, the exact number of patients exposed to the instruments used 
on the index patient could not be determined. Therefore, all patients who underwent surgical 
procedures from the time of the index patient's surgical procedure to the time at which the 
instruments were removed from circulation were regarded as potentially exposed to the 
contaminated instruments. Typically, before CJD was suspected, the neurosurgical 
instruments were reprocessed using conventional procedures, which included automated 
cleaning followed by standard steam autoclaving. After the CJD diagnosis, the instruments 
were taken out of circulation and subjected to the more stringent CJD decontamination 
protocols recommended by the CDC and the World Health Organization (WHO).6,9
Excluding 2 incidents that involved ophthalmologic procedures and 2 hospitals whose 
patient notification status is unknown, 12 (80%) of the remaining 15 hospitals decided to 
notify patients who were potentially exposed to inadequately sterilized neurosurgical 
instruments. Patient notification methods varied by hospital. Most hospitals sent out 
notification letters to affected patients. A limited number of hospitals used local newspaper 
advertisements as the sole notification method or in combination with mailed letters. In most 
cases, the postexposure message sent by hospital management was developed by 
multidisciplinary teams that included neurosurgeons, neurologists, infection prevention 
specialists, and hospital management staff.
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Many studies have evaluated the susceptibility of prions to chemical and physical 
inactivation methods (Table 2).10-22 Outcomes of these studies are influenced by the 
sterilization methods employed, the prion strains used, the nature of the starting material (eg, 
tissue macerates, brain homogenates, and contaminated stainless steel wires), and the 
laboratory method used to detect residual infectivity. To better simulate realistic hospital 
scenarios, more recent inactivation studies used stainless steel wires to evaluate the 
effectiveness of different decontamination and sterilization protocols.13,18-20 The wires were 
contaminated by immersing them in infected brain homogenate, and infectivity was assayed 
by implantation of the wires into the brain of experimental rodents. Studies that have used 
these methods have reported survival of prion infectivity after autoclaving at 134°C for 18 
minutes or more (Table 2).13-16,19,20,22 Two studies in particular reported survival of 
infectivity despite subjecting the wires to detergent washing before autoclaving at 134°C for 
18 minutes.15,19 In these same studies, a decontamination protocol with sodium hydroxide 
(NaOH) treatment followed by autoclaving at 134°C for 18 minutes was not completely 
effective, which indicates that prion sterilization protocols that combine chemical treatment 
with autoclaving should be carefully selected. Most effective decontamination protocols 
combining chemical treatment and autoclaving are summarized in Table 3.
DISCUSSION
Six cases of CJD, dating from the late 1950s to 1976, have been linked to exposure to prion-
contaminated neurosurgical instruments and devices.1,23 Four of these cases were associated 
with contaminated neurosurgical instruments, whereas 2 involved reuse of implantable 
electroencephalogram depth electrodes originally used in treating a patient with known 
CJD.24 Although the absence of CJD cases linked with exposure to neurosurgical equipment 
since the 1980s is reassuring, recent investigations have highlighted the difficulties 
associated with documenting such transmissions.1,25 In these investigations, an accurate 
assessment of a causal link with procedures that occurred many years in the past was not 
possible because of the unavailability of medical records and closure of hospitals. However, 
several studies have documented that a history of neurosurgical procedures among patients 
with CJD is uncommon, being reported in less than 4% of such patients.26-28
Infection prevention professionals’ awareness about the need for additional precautions 
when operating on patients with CJD has increased over the years, mainly because of 
increased publicity about the transmissibility of prion diseases and the resistance of prions to 
conventional sterilization methods. Despite this heightened awareness, incidents of patient 
exposure to inadequately sterilized neurosurgical instruments are reported to the CDC. 
Hospital staff often find themselves in a quandary when these incidents occur. Usually, 
weeks to months have elapsed by the time the incidents are discovered after confirmation of 
CJD in the index patient. Availability of multiple neurosurgical sets can hinder identification 
of the set used to treat the index patient, further complicating proper handling of these 
exposure incidents.
To prevent future occurrence of similar incidents, hospital infection prevention policies 
should be reviewed by integrating lessons learned from the unique characteristics of the CJD 
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incident under investigation. In 2011, the Joint Commission published a sentinel event alert 
summarizing lessons learned from a CJD exposure incident that can be applied to other 
hospitals.29 If not already in place, CJD infection prevention guidelines tailored to the 
institution should be developed and periodically updated as necessary. In over half of the 
exposure incidents described in Table 1, the intracranial procedures were likely performed 
as a diagnostic work-up for the patients. In such scenarios, exposures could potentially be 
prevented if CJD is included in the patient's presurgical assessment. Neurosurgical 
instruments used to treat patients whose diagnosis is unclear, particularly for brain biopsy, 
should be regarded as potentially contaminated with the CJD agent. Such instruments should 
be quarantined until a nonprion disease diagnosis is identified or should be regarded as 
contaminated and sterilized using the recommended CJD de-contamination protocols. 
Efficient communication among treating physicians, operating room staff, infection 
prevention professionals, and central sterilization department supervisors is crucial to ensure 
that appropriate measures are instituted to identify instruments that need special handling.
CJD exposure risk after neurosurgical procedures varies depending upon the type of 
procedure, number of neuro-surgical sets in circulation, time elapsed and number of 
operations performed after the procedure, and adequacy of routine instrument reprocessing 
methods (eg, multiple reprocessing and reuse). When assessing potential CJD exposure 
incidents, the following issues should be considered and critically evaluated.
Confirmation of CJD Diagnosis
Before taking drastic measures, such as notifying potentially exposed patients or exposing 
expensive instruments to harsh decontamination treatments, the CJD diagnosis should be 
confirmed in the index patient. Testing of brain tissue samples obtained at autopsy or biopsy 
is required to confirm a CJD diagnosis. Several types of tests can be performed on the brain 
tissue, including histopathology, immunohistochemistry, and Western blot analysis.30 Brain 
autopsy specimens have a higher diagnostic yield than brain biopsy specimens. Because 
CJD lesions are multifocal, careful sampling of the affected region is required to maximize 
the yield of brain biopsy testing.30 A negative brain biopsy result does not necessarily rule 
out a prion disease diagnosis. Cerebrospinal fluid (CSF) analysis for 14-3-3 and tau proteins 
can help in the clinical diagnosis of CJD; however, because they are nonspecific markers of 
rapid neuronal death, positive results do not confirm a CJD diagnosis.31 Recently, real-time 
quaking-induced conversion analysis of CSF has shown promising results as a premortem 
diagnostic tool by detecting the presence of minute amounts of prions.32 Whenever possible, 
diagnostic support should be obtained from sources experienced in diagnosing CJD, such as 
the National Prion Disease Pathology Surveillance Center. This pathology center was 
established by the CDC to provide prion disease diagnostic support to US physicians.30 If 
there is doubt about the diagnosis or while awaiting diagnostic clarification, the surgical 
instruments can be quarantined or reprocessed using the CJD decontamination protocols.
Type of Surgical Procedure
Risk of instrument contamination and potential for subsequent patient exposure depend on 
the type of procedure performed. Because the brain has the highest prion infectivity titer, 
intracranial procedures pose a higher risk of instrument contamination than ophthalmologic 
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procedures.6 Delicate, reusable instruments (eg, cranial probes) that are directly applied to 
the brain of patients with CJD but cannot be autoclaved pose a greater risk of prion exposure 
than instruments that can be autoclaved. It may be prudent to consider such instruments as 
single-use devices. The risk of instrument contamination during spinal surgical procedures, 
such as discectomy, laminectomy, and decompression procedures, should be considered 
equivalent to that associated with general surgical procedures performed in any other 
anatomical location. Spinal surgery that does not involve dural tear or direct contact with the 
spinal cord or CSF carries a lower risk of prion exposure than procedures involving 
manipulation of central nervous system tissues. No known CJD transmission via instruments 
used during ophthalmologic procedures has been reported. The only vehicles of CJD 
transmission involving ophthalmologic procedures were corneal grafts obtained from CJD 
decedents.33
Number of Neurosurgical Sets and Multiple Reuses
The CJD diagnosis for the index patient may not be suspected or confirmed until months 
after the initial neurosurgical procedure. During the interim, the instruments may have been 
used to treat many other patients and reprocessed multiple times using standard autoclaving 
methods. Multiple instrument reprocessing may be adequate to completely remove any 
residual prion infectivity. Modeling data developed by the UK CJD Incidents Panel 
indicated that most instruments reused and reprocessed for 10 or more cycles are unlikely to 
pose a significant risk of prion exposure to subsequent patients.34 The modeling scenarios 
used various assumptions that were derived from limited available data on prion 
contamination.
As shown in Table 1, almost half of the hospitals had multiple neurosurgical sets, which 
made identification of instruments used to treat the index patient with CJD nearly 
impossible. This created an additional level of complexity for hospitals that elected to notify 
patients who underwent a neurosurgical procedure before instrument sterilization using CJD 
decontamination protocols. All patients, including those who presumably underwent 
neurosurgical procedures using uncontaminated instruments, were included in the 
notification. The notification message should account for the likelihood that most patients 
probably were not exposed to the neurosurgical instruments used to treat the index patient. 
To avoid this confusion and allow identification of instruments used to treat specific 
patients, the feasibility of implementing instrument tracking procedures should be 
considered. In addition, as a general prudent practice, mixing instruments from 
neurosurgical sets with those of other general surgical sets should be avoided.
Management of Patients and Instruments after Exposure
Instruments used to treat patients whose CJD diagnosis was suspected or confirmed after a 
neurosurgical procedure should be reprocessed using CJD decontamination protocols as 
soon as possible after diagnosis. Alternatively, the instruments can be quarantined if the CJD 
diagnosis is unclear. The instruments should be kept moist by immersing them in saline 
during the quarantine period. If tracing of instruments used on the index patient is not 
possible, all neurosurgical sets should be treated with the CJD decontamination protocol, 
particularly if the instruments have not been reused and reprocessed for 10 or more cycles.
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Because patient exposure scenarios can be variable and the healthcare team and hospital 
management staff are more knowledgeable about the potential negative consequences of 
disclosure of such incidents, decisions about patient notification are best handled by an ad 
hoc hospital review board. In addition to the issues already discussed, the review board may 
wish to consider the following factors before making decisions: (1) the ability to identify 
potentially contaminated neurosurgical instruments and link them to exposed patients; (2) 
the low risk of transmission; (3) the potential negative consequences of informing patients 
about possible exposure to a fatal, untreatable brain disease with a long incubation period; 
(4) the absence of a practical CJD test to screen live patients; and (5) the absence of any 
meaningful intervention, such as prophylactic treatment, to ameliorate the risk of developing 
CJD.
Notification of potentially exposed patients creates ethical and legal concerns. However, no 
overriding public health justification exists to mandate notification of potentially exposed 
patients. Some exposed patients may have life-threatening conditions that led them to 
undergo the neurosurgical procedure in the first place. These patients may not survive long 
enough to develop CJD even if exposure was certain. Other patients may become severely 
depressed and suicidal upon hearing that they were exposed to an agent causing untreatable 
and invariably fatal disease. Therefore, the deleterious effects of patient notification should 
be carefully considered and balanced with the certainty of exposure, level of risk, and right 
of patients to be informed about their own exposure. In those incidents on which the CDC 
has consulted, a decision to notify potentially exposed patients was made by three-fourths of 
the hospitals. In the remaining hospitals, hospital staff reviewed the situation and decided 
that patient notification was unwarranted under those specific circumstances. Hospital 
review boards can differ in their recommendation regarding patient notification depending 
on the prevailing hospital policy, composition of the review board, number of patients 
involved, type of procedure, certainty of CJD diagnosis in the index patient, and time 
elapsed between potential instrument contamination and alleged patient exposure.
CJD Decontamination Protocols
Because of uncertainties inherent in inactivation studies and the variability of results 
depending on experimental design, some researchers may disagree on appropriate 
sterilization protocols to decontaminate neurosurgical instruments used to treat patients with 
CJD.5,7,35 In 1999, the WHO convened a consultation group of international prion disease 
experts to develop consensus infection control guidelines for prion diseases.6 Although over 
a decade has passed since the guidelines were developed, the key recommendations are still 
applicable and are endorsed by prion disease researchers at the CDC, US Food and Drug 
Administration, and National Institutes of Health, among other prominent prion disease 
experts.5 All surgical instruments that have direct contact with high- and low-infectivity 
tissues of patients with suspected or diagnosed prion disease should be sterilized using one 
of the options summarized in Table 3. The instruments should be kept moist by immersing 
them in saline to avoid air drying during and after the surgical procedure. The list of high- 
and low-infectivity tissues is periodically updated and summarized by the WHO.36 
Instruments used to treat patients with unclear diagnosis undergoing a craniotomy procedure 
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should be regarded as potentially contaminated and reprocessed using one of the options 
listed in Table 3 unless an alternative nonprion disease diagnosis is identified.
CJD-contaminated instruments may have been cleaned in an automated instrument washer 
together with other surgical instruments. However, cross-contamination of those instruments 
during the cleaning cycle is unlikely because enzymatic cleaners interfere with protein 
binding and alkaline pH aids in protein denaturation. Additionally, continuous water motion 
in the washer helps to keep such damaged proteins in suspension, thereby minimizing the 
potential that the CJD agent will stick to the instruments in the load. As a precaution, the 
washer could be run for an empty cycle after removing all instruments.6
Under option 1 in Table 3, contaminated instruments are autoclaved while immersed in IN 
NaOH solution. Options 2 and 3 allow for sequential treatment of instruments first by 
immersing them in IN NaOH or sodium hypochlorite followed by autoclaving. Unlike 
option 3, option 2 allows maintenance of instrument moistness as the instruments are 
transferred from the chemical directly into water and decontaminated by gravity 
displacement autoclaving while immersed in water. At the conclusion of the 
decontamination step, all 3 options require additional routine sterilization of the instruments 
by conventional washing and autoclaving used in the hospital (Table 3).
NaOH and sodium hypochlorite are corrosive chemicals, and their handling requires suitable 
personal protective equipment and proper secondary containment. The use of appropriate 
containment pans and lids has been shown to prevent escape of NaOH vapors and spills that 
may damage the autoclave.37 Because NaOH is much less corrosive, its use is preferred to 
that of sodium hypochlorite. An experimental study indicated that much of the instrument 
damage from autoclaving in NaOH was cosmetic and would not affect instrument 
performance.38
CONCLUSIONS
CJD exposure incidents create infection control management dilemmas that are further 
complicated by the availability of multiple neurosurgical sets and difficulty in tracing 
contaminated instruments. Potential exposures can be prevented by including CJD in the 
patient's presurgical assessment, particularly if a brain biopsy is planned. Mixing 
neurosurgical instruments with general surgical sets should be avoided, and the feasibility of 
implementing instrument tracking procedures should be considered. The experiences and 
approaches summarized above can help infection prevention professionals manage potential 
exposure incidents should they occur in the future.
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TABLE 3
Prion Decontamination Protocols For Reusable Surgical Instruments and Surfaces
World Health Organization and Centers for Disease Control and Prevention recommended options
1. Immerse in 1 N or 2 N NaOH and heat in a gravity displacement autoclave at ≥121°C for 30 minutes in an appropriate container (see text, 
warnings, and references). Clean and sterilize by conventional means.
2. Immerse in 1 N NaOH or NaOCl 20,000 ppm for 1 hour. Transfer into water and autoclave (gravity displacement) at ≥121°C for 1 hour. 
Clean and sterilize by conventional means.
3. Immerse in 1N NaOH or NaOCl (20,000 ppm) for 1 hour. Rinse instruments with water, transfer to open pan, and autoclave at ≥121°C 
(gravity displacement) or at 134°C (porous load) for 1 hour. Clean and sterilize by conventional means.
Decontamination of surfaces
    Surfaces can be treated with 2N NaOH or sodium hypochlorite (20,000 ppm) for 1 hour.
    Ensure surfaces remain wet for entire time period and then rinse well with water.
    Before chemical treatment, it is strongly recommended that gross contamination of surfaces be reduced because the presence of excess 
organic material will reduce the strength of either NaOH or sodium hypochlorite solutions.
Warnings
    NaOH should not be autoclaved in aluminum containers or in contact with aluminum.
    Some poor-quality stainless steel instruments may be corroded by exposures to NaOH solutions; many metal instruments are corroded by 
exposures to NaOCl solutions.
    Autoclave containers should have rims and lids designed to allow NaOH condensates to collect and drip back into the pan.
    NaOH solutions are very caustic when hot and should be allowed to cool close to ambient temperature before handling using appropriate 
precautions
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